Analysts Set Expectations for MRSN Q1 Earnings

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mersana Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.15) EPS and Q4 2025 earnings at ($0.14) EPS.

A number of other brokerages also recently weighed in on MRSN. Citigroup initiated coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday. Finally, William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.25.

Mersana Therapeutics Stock Down 8.3 %

Shares of MRSN stock opened at $0.48 on Tuesday. The stock’s 50 day simple moving average is $0.84 and its 200 day simple moving average is $1.57. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. Mersana Therapeutics has a twelve month low of $0.48 and a twelve month high of $6.28. The company has a market capitalization of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $16.36 million during the quarter, compared to the consensus estimate of $7.71 million.

Institutional Trading of Mersana Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRSN. US Bancorp DE acquired a new stake in Mersana Therapeutics in the 3rd quarter valued at approximately $31,000. Los Angeles Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 8.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock worth $358,000 after purchasing an additional 14,240 shares in the last quarter. GSA Capital Partners LLP grew its holdings in shares of Mersana Therapeutics by 368.9% during the 3rd quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock worth $514,000 after purchasing an additional 213,814 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter worth approximately $52,000. Finally, HealthInvest Partners AB grew its holdings in shares of Mersana Therapeutics by 191.3% during the 3rd quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after purchasing an additional 353,721 shares in the last quarter. Institutional investors and hedge funds own 93.92% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.